PLEASANTON Calif., SINGAPORE and TOKYO, Jan. 10, 2011
/PRNewswire/ — TriReme Medical, Inc. (TriReme) today announced
that it has signed an exclusive distribution and sales agreement
for TriReme’s complete line of advanced peripheral and coronary
balloon dilatation catheters with Century Medical, Inc. (CMI), a
leading independent device distributor for the important Japanese
market.
TriReme recently received clearance from the U.S. Food and Drug
Administration (FDA) for the GliderXtreme™ PTA balloon
catheter, a highly differentiated balloon catheter with an expanded
matrix of sizes including longer balloon lengths, an atraumatic
tapered tip and shaft construction reinforced for torque
transmission and exceptional pushability. GliderXtreme™
is designed to cross difficult and highly diseased lesions to
restore blood flow in the complex peripheral anatomy. TriReme’s
coronary version of this product, known as the Glider™ PTCA
balloon catheter is a state-of-the-art catheter designed to
overcome the limitations of conventional balloon catheters in
treating complex disease by improving torque and push transmission.
The combined PTCA & PTA balloon markets represent more than a
$400 million catheter device revenue opportunity in Japan.
“CMI’s long and successful history of obtaining timely
regulatory approvals , launching new products , building strong
dedicated sales and marketing teams and rapidly expanding market
share makes it an ideal partner for us in Japan,” Dr. Eitan
Konstantino, President and CEO of TriReme said. “This agreement is
a critical step in the realization of our Asian strategy. We look
forward to working with CMI to develop this important market and to
move market adoption to TriReme’s line of product.”
Akira Hoshino, President and CEO of CMI, commented that, “We are
very pleased to have entered into this long-term distribution
agreement with TriReme. TriReme has proven itself quite
capable of cre
‘/>”/>
